Case Report
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 26, 2021; 9(33): 10382-10391
Published online Nov 26, 2021. doi: 10.12998/wjcc.v9.i33.10382
Heart failure as an adverse effect of infliximab for Crohn's disease: A case report and review of the literature
Thais Gagno Grillo, Luciana Rocha Almeida, Rodrigo Fedatto Beraldo, Mariana Barros Marcondes, Diego Aparecido Rios Queiróz, Daniel Luiz da Silva, Rodrigo Quera, Julio Pinheiro Baima, Rogerio Saad-Hossne, Ligia Yukie Sassaki
Thais Gagno Grillo, Luciana Rocha Almeida, Rodrigo Fedatto Beraldo, Mariana Barros Marcondes, Diego Aparecido Rios Queiróz, Julio Pinheiro Baima, Rogerio Saad-Hossne, Ligia Yukie Sassaki, Department of Internal Medicine, São Paulo State University (Unesp), Medical School, Botucatu 18618687, São Paulo, Brazil
Daniel Luiz da Silva, Department of Pathology, São Paulo State University (Unesp), Medical School, Botucatu 18618687, São Paulo, Brazil
Rodrigo Quera, Inflammatory Bowel Disease Program, Digestive Disease Center Clínica Universidad de los Andes, Santiago 7550000, Chile
Author contributions: All authors contributed to this manuscript; Grillo TG, Almeida LR, Beraldo RF, Marcondes MB, Queiróz DAR, Baima JP, Saad-Hossne R, and Sassaki LY contributed to the conception and design of the study, acquisition, analysis, and interpretation of the data, drafting the article, revising it critically for important intellectual content, and final approval of the version to be submitted; da Silva DL contributed to the description of the histopathological findings, critically reviewing the important intellectual content, and final approval of the version to be submitted; Quera R contributed to the analysis and interpretation of the data, revising the manuscript critically for important intellectual content, and final approval of the version to be submitted.
Informed consent statement: Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
Conflict-of-interest statement: The authors state that they have no conflicts of interest regarding this case report.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016) statement, and the manuscript was prepared and revised according to the CARE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Thais Gagno Grillo, MD, Medical Assistant, Department of Internal Medicine, São Paulo State University (Unesp), Medical School, Av. Prof. Mário Rubens Guimarães Montenegro, s/n, Botucatu 18618687, São Paulo, Brazil. thaisgagno@gmail.com
Received: July 11, 2021
Peer-review started: July 11, 2021
First decision: July 26, 2021
Revised: August 8, 2021
Accepted: September 8, 2021
Article in press: September 8, 2021
Published online: November 26, 2021
Core Tip

Core Tip: Anti-tumor necrosis factor agents were the first biologic therapy approved for the management of Crohn's disease (CD). While rare, heart failure (HF) is a potential adverse effect of these medications. In this report we describe a patient with CD who developed HF after treatment with infliximab. The clinical, diagnosis, imaging, and treatment details are all provided and discussed in this case report. This reported case supports the need to investigate risk factors for HF in inflammatory bowel disease patients and to consider the risk-benefit of introducing infliximab therapy in such patients presenting with HF risk factors.